检索结果-南通市图书馆

Pegylated Liposomal Doxorubicin as a Single Agent or as Combination Therapy with Carboplatin in Patients with Recurrent or Refractory Epithelial Ovarian Cancer

在线全文

学校读者我要写书评

暂无评论

Clinical oncology and cancer researeh 2009年第6期6卷 387-393页

作者： Beihua Kong yunong gao Lingying Wu Ziting Li Yile Chen Mengda Li Yongliang gao Ding ga Zhilan Peng KengShen Peking Union Medical College Hospital Beijing China Shandong University Qilu Hospital Jinan Shandong Province China Beijing Oncology Hospital Beijing China Cancer Hospital and Institute Chinese Academy of Medical Sciences Beijing China Fudan University Cancer Hospital Shanghai China Hunan Province Oncology Hospital Changsha Hunan Province China Sun Yat-Sen University Cancer Center Guangzhou Guangdong Province China Zhejiang Province Oncology Hospital Hangzhou Zhejiang Province China Tongji Hospital of Tongji Medical College of Huazhong University of Science & Technology Wuhan Hubei Province China West China Second Hospital of Sichuan University Chengdu Sichuan Province

OBJECTIVE Pegylated liposomal doxorubicin （PLD; CAELYX ）, a novel formulation of doxorubicin with enhanced therapeutic efficacy and reduced toxicity, has demonstrated improved progression-free survival in recurrent or refractory ovarian cancer. The objective of this open-label, noncomparative, observational study was to determine the efficacy and safety of PLD monotherapy or combination therapy with carboplatin for patients with cancer. recurrent or refractory ovarian METHODS Sixty-two patients with recurrent or refractory ovarian cancer who completed a platinum-based chemotherapy regimen and demonstrated platinum sensitivity for first-line treatment at least 6 months prior to study entry were enrolled in 20 centers in China. PLD was given as monotherapy （50 mg/m2 infused over 60 minutes） or as combination therapy （30 mg/m2 1-hour infusion） with carboplatin （area under the curve 5 ***/mL 1-hour infusion） on day 1 every 28 days for 4 cycles. The primary endpoint was objective response （OR） rate or CA-125 level. Secondary endpoints included time to response, time-to-progression, health-related quality of life, and safety. RESULTS Overall, 48% of the 62 evaluable patients achieved a confirmed OR. More patients receiving PLD and carboplatin achieved an OR vs the PLD monotherapy group （63% vs. 37%）. The median time to response and disease progression was 58.5 days and 56.0 days, respectively. Overall and drug-related adverse events were reported for 39% and 34%, respectively. The most commonly reported adverse events were stomatitis （22.6%） and palmar-plantar erythroderma （9.7%）. Two deaths were reported. CONCLUSION PLD is an effective and well tolerated agent in women with recurrent or refractory epithelial ovarian cancer.

关键词： carboplatin ovarian cancer pegylated liposomal doxorubicin recurrent refractory.

在线全文

学校读者我要写书评

暂无评论

子宫内膜癌的化疗与内分泌治疗

中国实用妇科与产科杂志 2017年第5期33卷 469-472页

作者：高雨农北京大学肿瘤医院北京100142

文章总结了子宫内膜癌术后辅助化疗、术前新辅助化疗和内分泌治疗等问题。术后辅助化疗主要用于晚期子宫内膜癌及早期患者术后具有高危因素的病例。铂与紫杉醇联合应用是目前子宫内膜癌辅助治疗的首选方案。新辅助化疗主要应用于晚期病... 详细信息

文章总结了子宫内膜癌术后辅助化疗、术前新辅助化疗和内分泌治疗等问题。术后辅助化疗主要用于晚期子宫内膜癌及早期患者术后具有高危因素的病例。铂与紫杉醇联合应用是目前子宫内膜癌辅助治疗的首选方案。新辅助化疗主要应用于晚期病例,以使随后的减瘤术顺利完成。内分泌治疗虽然没有得到肯定,但是在晚期病例经常用到。

关键词：子宫内膜肿瘤化疗新辅助化疗激素治疗

Tislelizumab in previously treated,locally advanced unresectable/metastatic microsatellite instability-high/mismatch repair-deficient solid tumors

在线全文

学校读者我要写书评

暂无评论

Chinese Journal of Cancer Research 2024年第3期36卷 257-269页

作者： Jian Li Ye Xu Aimin Zang yunong gao Quanli gao Yanqiao Zhang Dong Wang Jianming Xu Ying Yuan Haiping Jiang Jieer Ying Chunmei Shi Yanhong Deng Jing Wang Tianshu Liu Yi Huang Xiaoping Qian Yueyin Pan Ying Cheng Sheng Hu Jin Wang Mengyue Shi Ke Wang Han Hu Lin Shen State Key Laboratory of Holistic Integrative Management of Gastrointestinal Cancers Beijing Key Laboratory of Carcinogenesis and Translational ResearchDepartment of Gastrointestinal OncologyPeking University Cancer Hospital&InstituteBeijing 100142China Department of Oncology Fudan University Shanghai Cancer CenterShanghai 200032China Department of Medical Oncology Affiliated Hospital of Hebei UniversityBaoding 071000China Key Laboratory of Carcinogenesis and Translational Research(Ministry of Education/Beijing) Department of GynecologyPeking University Cancer Hospital&InstituteBeijing 100142China Department of Immunotherapy Henan Cancer HospitalZhengzhou 450001China Department of Gastrointestinal Oncology Affiliated Cancer Hospital of Harbin Medical UniversityHarbin 150086China Department of Gastrointestinal Oncology Chongqing University Cancer HospitalChongqing 400030China Department of Gastrointestinal Oncology the Fifth Medical CenterChinese PLA General HospitalBeijing 100048China Department of Medical Oncology the Second Affiliated HospitalZhejiang University School of MedicineHangzhou 310009China Department of Medical Oncology the First Affiliated HospitalZhejiang University School of MedicineHangzhou 310003China Department of Medical Oncology Cancer Hospital of the University of Chinese Academy of SciencesHangzhou 310022China Department of Medical Oncology Fujian Medical University Union HospitalFuzhou 350001China Department of Oncology the Sixth Affiliated HospitalSun Yat-sen UniversityGuangzhou 510655China Department of Medical Oncology Hunan Cancer HospitalChangsha 410013China Department of Medical Oncology Zhongshan HospitalFudan UniversityShanghai 200032China Department of Immunotherapy Hubei Cancer HospitalWuhan 430079China Department of Medical Oncology the Affiliated Hospital of Nanjing University Medical SchoolNanjing 210008China Department of Medical Oncology Anhui Provincial HospitalHefei 230001China Department of Medical Oncology Jilin Cancer Hospital

Objective:The open-label,phase II RATIONALE-209 study evaluated tislelizumab(anti-programmed cell death protein 1 antibody)as a tissue-agnostic monotherapy for microsatellite instability-high(MSI-H)/mismatch repair-deficient(dMMR)***:Adults with previously treated,locally advanced unresectable or metastatic MSI-H/dMMR solid tumors were *** received tislelizumab 200 mg intravenously every 3 *** response rate(ORR;primary endpoint),duration of response(DoR),and progression-free survival(PFS)were assessed by independent review committee(Response Evaluation Criteria in Solid Tumors v1.1).Results:Eighty patients were enrolled and treated;75(93.8%)patients had measurable disease at *** had metastatic disease and received at least one prior therapy for advanced/metastatic disease(n=79;98.8%).At primary analysis(data cutoff July 8,2021;median follow-up 15.2 months),overall ORR[46.7%;95%confidence interval(95%CI),35.1−58.6;one-sided P<0.0001]and ORR across tumor-specific subgroups[colorectal(n=46):39.1%(95%CI,25.1–54.6);gastric/gastroesophageal junction(n=9):55.6%(95%CI,21.2−86.3);others(n=20):60.0%(95%CI,36.1−80.9)]were significantly greater with tislelizumab vs.a prespecified historical control ORR of 10%;five(6.7%)patients had complete *** DoR,PFS,and overall survival were not reached with long-term follow-up(data cutoff December 5,2022;median follow-up 28.9 months).Tislelizumab was well tolerated with no unexpected safety ***-related adverse events(TRAEs)of grade≥3 occurred in 53.8%of patients;7.5%of patients discontinued treatment due to ***:Tislelizumab demonstrated a significant ORR improvement in patients with previously treated,locally advanced unresectable or metastatic MSI-H/dMMR tumors and was generally well tolerated.

关键词： Biomarkers DNA mismatch repair immune checkpoint inhibitors microsatellite instability phase II clinical trials programmed cell death 1 receptor

血清人附睾分泌蛋白4及CA125在子宫内膜癌术前评估和预后判断中的应用

在线全文

学校读者我要写书评

暂无评论

中国妇产科临床杂志 2019年第5期20卷 392-394页

作者：张乃怿高雨农高敏北京大学肿瘤医院暨北京市肿瘤防治研究所肿瘤妇科 100142 北京大学恶性肿瘤发病机制及转化研究重点实验室 100142

目的评估血清HE4和CA125在术前预估是否需行淋巴结切除的作用。方法入组患者145例,术前留取血液样本行HE4和CA125检测。HE4和CA125与病理学特征和预后的比较采用Mann-Whitney U检验。绘制ROC曲线选择HE4最佳的诊断界限值,计算灵敏度、... 详细信息

目的评估血清HE4和CA125在术前预估是否需行淋巴结切除的作用。方法入组患者145例,术前留取血液样本行HE4和CA125检测。HE4和CA125与病理学特征和预后的比较采用Mann-Whitney U检验。绘制ROC曲线选择HE4最佳的诊断界限值,计算灵敏度、特异度。结果平均随访40.7个月。HE4在深肌层浸润、卵巢转移、盆腔淋巴结转移及腹主动脉旁淋巴结转移的患者中明显增高。以HE4>61.2 pmol/L作为深肌层浸润的诊断指标时,灵敏度为80.0%,特异度为69.1%。以HE4>61.2 pmol/L作为判断腹主动脉旁淋巴结转移的诊断指标时,灵敏度为87.5%,特异度为56.6%。结论血清HE4与内膜癌的高危病理因素和不良预后有密切关联,HE4检测有助于术前预估内膜癌是否需行淋巴结切除和判断预后。

关键词：附睾分泌蛋白4 CA125 子宫内膜癌淋巴结清扫术

术后应用低分子肝素联合逐级加压弹力袜预防妇科恶性肿瘤患者静脉血栓栓塞性疾病

在线全文

学校读者我要写书评

暂无评论

中华肿瘤杂志 2014年第1期36卷 39-42页

作者：郑虹高雨农燕鑫高敏高维娇北京大学肿瘤医院暨北京市肿瘤防治研究所妇科恶性肿瘤发病机制及转化研究教育部重点实验室 100142

目的探讨妇科恶性肿瘤患者术后应用低分子肝素（LMWH）联合逐级加压弹力袜预防静脉血栓栓塞性疾病（vTE）的效果。方法按照术后预防VTE的不同方法，将行根治性手术治疗的妇科恶性肿瘤初治患者分为2组，分别为LMWH联合弹力袜组和弹力袜... 详细信息

目的探讨妇科恶性肿瘤患者术后应用低分子肝素（LMWH）联合逐级加压弹力袜预防静脉血栓栓塞性疾病（vTE）的效果。方法按照术后预防VTE的不同方法，将行根治性手术治疗的妇科恶性肿瘤初治患者分为2组，分别为LMWH联合弹力袜组和弹力袜组，分析2组患者预防VTE的效果。结果LMWH联合弹力袜组患者术后VTE的发生率为0．8％，低于弹力袜组（8．1％，P=0．01）。应用LMWH的患者术后未发生严重的出血并发症，而伤口裂开的发生率与未应用LMWH的患者比较，差异无统计学意义（P〉0．05）。多因素Logistic回归分析结果显示，年龄≥60岁、手术时间≥3h和未应用LMWH是术后发生VTE的独立危险因素（均P〈0．05）。结论妇科恶性肿瘤患者术后应用LMWH联合弹力袜预防vTE的效果高于单独应用弹力袜，且方便、安全。患者高龄和手术时间长是术后发生VrrE的危险因素，应给予积极有效的预防措施。

关键词：肿瘤继发原发性生殖器肿瘤女(雌)性静脉血栓栓塞性疾病外科手术预防和防护用药

阿瑞匹坦联合地塞米松及昂丹司琼预防妇科肿瘤患者顺铂化疗引起的恶心呕吐的效果观察

在线全文

学校读者我要写书评

暂无评论

实用妇产科杂志 2017年第1期33卷 57-61页

作者：张乃怿高雨农北京大学肿瘤医院暨北京市肿瘤防治研究所恶性肿瘤发病机制及转化研究教育部重点实验室北京100142

目的:通过前瞻性观察评价阿瑞匹坦联合地塞米松及昂丹司琼预防妇科肿瘤患者接受含顺铂化疗引起的恶心呕吐(CINV)的效果。方法:采用前瞻性研究方法选择2013年12月1日至2014年9月30日收治的妇科肿瘤患者70例,均接受含有顺铂的单日或多日... 详细信息

目的:通过前瞻性观察评价阿瑞匹坦联合地塞米松及昂丹司琼预防妇科肿瘤患者接受含顺铂化疗引起的恶心呕吐(CINV)的效果。方法:采用前瞻性研究方法选择2013年12月1日至2014年9月30日收治的妇科肿瘤患者70例,均接受含有顺铂的单日或多日化疗方案,并给予阿瑞匹坦联合地塞米松及昂丹司琼的三联预防性止吐治疗。在整个研究期间通过患者研究日志记录其对治疗的反应。主要研究终点为完全缓解率,次要研究终点包括急性期完全缓解率、延迟期完全缓解率、完全保护率、完全控制率、危险因素和预期因素对完全缓解率的影响以及CINV对日常生活的影响。结果:70例患者中完全缓解率为80.0%,急性期完全缓解率为94.3%,延迟期完全缓解率为84.3%;完全保护率为42.9%,完全控制率为25.7%;71.4%的患者表示CINV对日常生活影响极小。结论:阿瑞匹坦联合地塞米松及昂丹司琼可有效预防妇科肿瘤患者接受含顺铂的化疗引起的呕吐,但三药联合方案对预防恶心的作用仍欠满意,用于多日化疗的最佳用药方案尚需进一步研究。接受顺铂化疗的妇科肿瘤患者,在应用三联止吐方案后,CINV对多数患者生活质量的影响很小。

关键词：化疗引起的恶心呕吐预防性治疗顺铂阿瑞匹坦地塞米松昂丹司琼

Comparison of two methods for evaluating lower urinary tract symptoms in cervical cancer patients following radical hysterectomy

在线全文

学校读者我要写书评

暂无评论

Gynecology and Obstetrics Clinical Medicine 2021年第2期1卷 70-74页

作者： Fang An Sha Wang Zhiqi Wang Lingying Wu Qiubo Lv Aiming Lv Hongwu Wen Jinsong Han Yumei Wu yunong gao Qing Liu Sumei Wang Hongxia Li Luwen Wang Yanlong Wang Ruifang Wu Huan Li Xiuli Sun Department of Obstetrics and Gynecology Peking University People’s HospitalBeijing100044China Beijing Key Laboratory of Female Pelvic Floor Disorders BeijingChina Female Pelvic Floor Disease Research Center Peking UniversityBeijingChina The Research Center of Female Pelvic Floor Dysfunction and Disease of Peking University People’s Hospital BeijingChina Cancer Hospital Chinese Academy of Medical Sciences BeijingChina Beijing Hospital BeijingChina Peking University First Hospital BeijingChina Peking University Third Hospital BeijingChina Beijing Obstetrics and Gynecology Hospital Capital Medical UniversityBeijing Maternal and Child Health Care HospitalBeijingChina Beijing Cancer Hospital&Beijing Institute for Cancer Research BeijingChina Gansu Provincial Maternity and Child-care Hospital GansuChina Beijing Chao-yang Hospital Capital Medical UniversityBeijingChina Beijing Shi Ji Tan Hospital BeijingChina The Third Affiliated Hospital of Zhengzhou University ZhengzhouChina Xiamen Maternal and Child Health Hospital XiamenChina Peking University Shenzhen Hospital ShenzhenChina

Objective:To compare the degree of agreement and consistency of urodynamic studies(UDS)with low urinary tract symptoms(LUTS)questionnaires for evaluating LUTS in cervical cancer patients following radical hysterectomy(RH)and pelvic ***:From January 2012 to March 2015,204 cervical cancer patients who underwent RH in 13 hospitals were evaluated using the Incontinence Questionnaire-Female Lower Urinary Tract Symptoms(ICIQ-FLUTS)and the Overactive Bladder Symptom Score(OABSS).Urodynamic tests were also performed on these patients during the same ***:Study participants’age ranged from 23 to 75 years,with a mean(standard deviation)of 48.0±9.3 *** questionnaires,the prevalence of patients with LUTS symptoms,including storage symptoms,voiding symptoms,stress urinary incontinence(SUI)and overactive bladder(OAB)was 86.3%,77.0%,62.7%,52.9%and 14.7%,*** UDS,the corresponding prevalence was 89.7%,70.1%,66.7%,46.6%and 13.2%,*** diagnostic concordance of questionnaires and UDS for storage symptoms,voiding symptoms,SUI and OAB was 79.9%,66.7%,66.7%,57.4%and 79.9%,*** voiding symptoms,the correlation coefficient was 0.272,which was higher than that of storage symptoms,SUI and OAB.

关键词： Cervical cancer Radical hysterectomy Lower urinary tract symptoms Urodynamics

从金代红绿彩瓷看北方少数民族文化的发展与变化

维普期刊数据库评论

在线全文

维普期刊数据库

学校读者我要写书评

暂无评论

陶瓷 2021年第11期 65-67页

作者：高雨农景德镇陶瓷大学江西景德镇333000

金代是我国历史上由少数民族建立的重要政权朝代。以时间概念来描述金与宋相重合,故这个由女真族建立起来的少数民族政权在发展过程中或多或少都受到了中原文化的影响。金代陶瓷是我国古代陶瓷发展史上重要的组成部分,而金代彩瓷无疑是... 详细信息

金代是我国历史上由少数民族建立的重要政权朝代。以时间概念来描述金与宋相重合,故这个由女真族建立起来的少数民族政权在发展过程中或多或少都受到了中原文化的影响。金代陶瓷是我国古代陶瓷发展史上重要的组成部分,而金代彩瓷无疑是其中璀璨的明珠。以往对于金代陶瓷的研究较为稀缺,仅有的也多是以造型、装饰等方面展开,但对于其中所蕴含着的民族文化发展演变分析较少。所以笔者以金代陶瓷中的珍宝——红绿彩瓷为载体,对金代少数民族文化的发展、变化、影响进行分析,以期丰富关于我国金代陶瓷和少数民族文化方面的研究。

关键词：金代陶瓷彩瓷

在线全文

学校读者我要写书评

暂无评论

宫颈癌的化疗

中华妇幼临床医学杂志（电子版） 2015年第6期11卷 682-684页

作者：高雨农北京大学肿瘤医院暨北京市肿瘤防治研究所恶性肿瘤发病机制及转化研究教育部重点实验室100142

宫颈癌的主要治疗方案是手术和放疗,近年由于对宫颈癌综合治疗方案的广泛应用,特别是手术技术的改进,保留生育手术的兴起,使宫颈癌化疗逐渐受到重视。宫颈癌的化疗包括同步放化疗、术前新辅助化疗、术后辅助化疗及姑息化疗。新辅助化疗... 详细信息

宫颈癌的主要治疗方案是手术和放疗,近年由于对宫颈癌综合治疗方案的广泛应用,特别是手术技术的改进,保留生育手术的兴起,使宫颈癌化疗逐渐受到重视。宫颈癌的化疗包括同步放化疗、术前新辅助化疗、术后辅助化疗及姑息化疗。新辅助化疗虽然在临床中应用广泛,但其疗效迄今仍尚未确定,而同步放化疗却得到了临床的进一步肯定。宫颈癌姑息治疗中的化疗,不能改善患者的远期生存质量。因此,化疗仍然是宫颈癌治疗的辅助手段。

关键词：宫颈肿瘤放射疗法,辅助新辅助化疗,术前化学疗法,辅助同步放化疗姑息疗法女性